Vigilance over HIV drug interactions still needed
Intermittent and lower-risk PrEP users may not be testing for HIV and STIs, German study finds
How do we deal with apparent cases of PrEP failure?
96-week results of DISCOVER PrEP trial presented at European AIDS Conference
Options for two-drug simplification expand
Tenofovir (TDF) does not increase risk of kidney disease in people at low risk
HIV-positive gay men in England report highest chemsex rates in four-country survey
Dolutegravir and raltegravir cause changes to fat cells
Weight gain after switching to integrase inhibitor treatment is small in Dutch and Swiss cohorts
French study finds one in six stops PrEP within 12 months, one in three after 30 months
New European HIV guidelines cater for multiple needs
Anal cancer: Australian study of precancerous tissues in gay men shows little increased risk in positive men, almost no cancer cases
ADVANCE study shows high frequency of major weight gain in women receiving dolutegravir with TAF
Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for cause
Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe
Rugby star Gareth Thomas speaks out against HIV stigma at European AIDS Conference
